View More Recent Stories

May 26, 2021 07:30AM Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference
May 14, 2021 07:00AM Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Huma
May 14, 2021 07:00AM Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic
May 6, 2021 07:29AM Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
May 6, 2021 07:29AM Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
Apr 27, 2021 04:35PM New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting
Apr 27, 2021 04:35PM New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting
Mar 4, 2021 07:35AM Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
Mar 4, 2021 07:35AM Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
Mar 4, 2021 07:26AM Dyne Therapeutics Inc. (DYN) Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
Mar 4, 2021 07:25AM Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
Mar 4, 2021 07:25AM Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
Feb 8, 2021 07:30AM Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
Feb 8, 2021 07:30AM Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
Jan 10, 2021 03:00PM Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
Jan 10, 2021 03:00PM Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
Jan 5, 2021 07:30AM Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Jan 5, 2021 07:30AM Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Nov 9, 2020 07:30AM Dyne Therapeutics to Present at Upcoming Investor Conferences
Nov 9, 2020 07:30AM Dyne Therapeutics to Present at Upcoming Investor Conferences
Nov 5, 2020 07:35AM Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights
Nov 5, 2020 07:35AM Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights
Feb 9, 2017 09:24AM Pre-Open Movers 02/09: (OSUR) (ACOR) (PAYC) Higher; (TWTR) (OII) (QLYS) Lower (more...)
Jan 25, 2016 07:33AM Wall Street resumes 2016 slide as energy stocks tumble
View More Recent Stories